IPOs

Found 16,657 articles

• Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering

  5/22/2023

  DAXOR CORPORATION today announced the pricing of its previously announced underwritten public offering of 410,260 shares of its common stock at a public offering price of $9.75 per share. Gross proceeds from the offering are expected to be approximately $4.0 million before deducting underwriting discounts, commissions, and estimated offering expenses.

• Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index

  5/22/2023

  Lineage Cell Therapeutics, Inc. today reported that the Company is expected to be added to the broad-market Russell 3000 ® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective as of the U.S. market open on June 26, 2023, according to a preliminary list of additions posted to the FTSE Russell website, following the close of the U.S. markets on May 19, 2023.

• TransCode Therapeutics Announces 1-for-20 Reverse Stock Split

  5/22/2023

  TransCode Therapeutics, Inc. today announced that its Board of Directors approved a 1-for-20 reverse stock split, to be effective 4:05 p.m. Eastern Time today, May 22, 2023.

• Sigilon Announces Reverse Stock Split of Common Stock

  5/22/2023

  Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock.

• Krystal Biotech Announces $160 Million Private Placement Equity Financing

  5/22/2023

  Krystal Biotech, Inc. today announced that it has entered into a securities purchase agreement for the sale of 1,729,729 shares of its common stock at $92.50 per share in a private placement (the PIPE) to certain qualified institutional buyers.

• Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  5/22/2023

  Repare Therapeutics Inc. today announced that, in connection with the appointment of Daniel Belanger as the Company’s EVP, Human Resources, the Company granted Mr. Belanger an inducement stock option to purchase an aggregate of 240,000 of the Company’s common shares.

• Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

  5/19/2023

  Intercept Pharmaceuticals, Inc. today announced that NASDAQ has halted trading of the company’s common stock.

• IQVIA Announces Offering of Senior Secured Notes and Senior Notes

  5/18/2023

  IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $1,000,000,000 through an offering of senior secured notes due 2028 and senior notes due 2030 (collectively, the “Notes”).

• LadRx Announces Reverse Stock Split Effective as of May 17, 2023

  5/18/2023

  LadRx Corporation today announced that its previously announced reverse stock split of its common stock at a ratio of 1 post-split share for every 100 pre-split shares became effective at 5:00 a.m. PDT on Wednesday, May 17, 2023.

• Prelude Therapeutics Announces Pricing of Public Offering

  5/18/2023

  Prelude Therapeutics Incorporated today announced the pricing of its underwritten public offering of 3,048,522 shares of its voting common stock and 1,448,222 shares of its non-voting common stock, each at a price to the public of $5.75 per share, and, in lieu of common stock to investors who so choose.

• Biocept Announces One-for-Thirty Reverse Stock Split

  5/17/2023

  Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its 1-for-30 reverse stock split that became effective at 4:05 p.m. Eastern Time on May 16, 2023, its common stock will begin trading on a split-adjusted basis with the open of the market today, May 17, 2023.

• Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

  5/17/2023

  Spectrum Pharmaceuticals, Inc. announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

• Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering

  5/16/2023

  Acurx Pharmaceuticals, Inc. today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,333,333 shares of common stock and unregistered Series D warrants to purchase up to an aggregate of 1,333,333 shares of common stock.

• X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-MarketX4 WHIM Phase 3 clinical data webinar to be held today at 4 pm ET

  5/16/2023

  X4 Pharmaceuticals, Inc. today announced that it has agreed to sell an aggregate of 42,784,203 shares of common stock (or pre-funded warrants in lieu thereof) to certain institutional accredited investors in a private investment in public equity (PIPE) financing.

• Modular Medical Announces Pricing of Upsized $9.4 Million Public Offering

  5/16/2023

  Modular Medical, Inc. today announced the pricing of an upsized underwritten public offering of 8,816,900 shares of its common stock and warrants to purchase 4,408,450 shares of its common stock.

• MindBio Therapeutics Chief Executive Officer Issues Letter to Shareholders Discussing the Company’s Growth Plans

  5/16/2023

  MindBio Therapeutics Corp. today issued a letter to shareholders from Justin Hanka, Co-Founder and Chief Executive Officer of MindBio.

• Ikena Oncology Announces $40 Million Underwritten Offering

  5/15/2023

  Ikena Oncology, Inc. announced today the pricing of an underwritten offering of 6,110,000 shares of common stock (the “Shares”) at an offering price of $6.55 per share.

• Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2023

  5/15/2023

  Zimmer Biomet Holdings, Inc. today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2023.

• PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

  5/11/2023

  PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest.

• Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

  5/10/2023

  Pulse Biosciences, Inc. today announced that it intends to deliver an irrevocable notice of redemption, on or about May 15, 2023, to redeem all of the common stock warrants that were issued as part of its June 9, 2022 rights offering which are still outstanding as of June 16, 2023.